![]() ![]() Recently he collaborated with Helsinn on the development of the second generation 5-HT3 and NK1 receptor antagonists, palonosetron and netupitant, respectively. Pioneered the use of the ferret to model chemotherapy-induced acute and delayed emesis (now a gold standard model) and discovered that NK1 tachykinin antagonists could be used to prevent the acute and delayed phases of emesis induced by cisplatin: now NK1 tachykinin antagonists are a cornerstone of treatment for delayed emesis. ![]() He was also part of a team that mapped 5-HT3 receptor distribution in the human and ferret brainstem and first to show increases in of 5-HT in the plasma of patients receiving cisplatin-based chemotherapy. RUDD John Anthony (陸臻賢) worked with Glaxo Group Research in the late 1980s to explore the potential use of the 5-HT3 receptor antagonist, ondansetron, to antagonize chemotherapy- and drug-induced emesis. You need JavaScript enabled to view it.ħ04A, Lo Kwee-Seong Integrated Biomedical Sciences Building, Area 39, CUHK Featured Interviews and Column ArticlesĮ-mail: This email address is being protected from spambots.SBS Postgraduate Research Day (Restricted download area).SBS Annual Reports and Anniversary Booklets.Students’ and Alumni’s Awards and Updates."Silent Teacher" Body Donation Programme.Neural, Vascular, and Metabolic Biology.Cancer Biology and Experimental Therapeutics.Career Opportunities at the Dalton laboratory. ![]()
0 Comments
Leave a Reply. |